Metformin reduces C-reactive protein but not complement factor C3 in overweight patients with Type 2 diabetes mellitus

被引:47
作者
Carter, AM [1 ]
Bennett, CE [1 ]
Bostock, JA [1 ]
Grant, PJ [1 ]
机构
[1] Univ Leeds, Fac Med & Hlth, Leeds Inst Genet Hlth & Therapeut, LIGHT Labs, Leeds LS2 9JT, W Yorkshire, England
关键词
Type 2 diabetes mellitus; metformin; C-reactive protein; complement C3;
D O I
10.1111/j.1464-5491.2005.01632.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims To determine the influence of metformin treatment on plasma C-reactive protein (CRP) and complement factor C3. Methods A double-blind, placebo-controlled trial of metformin in patients with poorly controlled Type 2 diabetes mellitus and body mass index > 25 kg/m(2). CRP and C3 were analysed in stored plasma samples by in-house ELISAs. Patients attended two baseline visits before randomization and subsequently attended at 3, 6, 12 and 24 weeks post randomization. All patients gave informed consent according to a protocol approved by the Leeds Teaching Hospitals Research Ethics Committee. Results Baseline CRP in the patients randomized to placebo [1.33 (0.79, 2.25) mg/l] and metformin [1.24 (0.89, 1.71) mg/l] were similar (P = 0.8). Baseline CRP correlated with baseline C3 (r = 0.366) and HbA(1c) (r = 0.327). The difference in ratios of CRP levels at each visit to baseline between placebo- (n = 16) and metformin-treated (n = 26) subjects was significantly different at the 12-week (P = 0.002) and 24-week (P = 0.03) visits. The difference in CRP ratios between the two treatment groups remained significant after accounting for glycaemic control at both visits (P = 0.001 and P = 0.003, respectively). Baseline C3 was correlated with CRP. Baseline C3 was lower in the placebo-treated group [0.97 (0.88, 1.05) mg/ml] compared with the metformin-treated group [1.09 (1.02, 1.17) mg/ml, P = 0.03]. There was no difference in the mean change in C3 at any visit from baseline between placebo- and metformin-treated groups. Conclusion Metformin may have a specific interaction with mechanisms involved in CRP synthesis or secretion, not directly related to improved insulin sensitivity and dampening of chronic inflammation.
引用
收藏
页码:1282 / 1284
页数:3
相关论文
共 18 条
[1]   Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes [J].
Chu, NV ;
Caulfield, M ;
Kong, APS ;
Mudaliar, SR ;
Kim, DD ;
Reitz, R ;
Armstrong, D ;
Henry, RR ;
Baxi, S ;
Reaven, PD ;
Deutsch, R .
DIABETES CARE, 2002, 25 (03) :542-549
[2]   EFFICACY OF METFORMIN IN PATIENTS WITH NON-INSULIN-DEPENDENT DIABETES-MELLITUS [J].
DEFRONZO, RA ;
GOODMAN, AM ;
ABELOVE, W ;
REID, E ;
PITA, J ;
CALLAHAN, M ;
JOHNSON, D ;
PELAYO, E ;
PUGH, J ;
SHANK, M ;
GARZA, P ;
HAAG, B ;
KORFF, J ;
ANGELO, A ;
IZENSTEIN, B ;
VANDERLEEDEN, M ;
CATHCART, H ;
TIERNEY, M ;
BIGGS, D ;
KARAM, J ;
NOLTE, M ;
GAVIN, L ;
ELDER, MA ;
CORBOY, J ;
THWAITE, D ;
WONG, S ;
DAVIDSON, M ;
PETERS, A ;
DUNCAN, T ;
KERCHER, S ;
FISCHER, J ;
KIPNES, M ;
RADNICK, BJ ;
ROURA, M ;
ROQUE, J ;
MONTGOMERY, C ;
COLLUM, P ;
RUST, M ;
POHL, S ;
PFEIFER, M ;
ALLWEISS, P ;
LEICHTER, S ;
LEACH, P ;
GALLINA, D ;
MUSEY, V ;
BERKOWITZ, K ;
EASTMAN, R ;
TAYLOR, T ;
DELAPENA, MS ;
ZAWADSKI, J .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (09) :541-549
[3]   Troglitazone reduces hyperglycaemia and selectively acute-phase serum proteins in patients with Type II diabetes [J].
Ebeling, P ;
Teppo, AM ;
Koistinen, HA ;
Viikari, J ;
Rönnemaa, T ;
Nissén, M ;
Bergkulla, S ;
Salmela, P ;
Saltevo, J ;
Koivisto, VA .
DIABETOLOGIA, 1999, 42 (12) :1433-1438
[4]   The effects of high- and medium-dose metformin therapy on cardiovascular risk factors in patients with type II diabetes [J].
Grant, PJ .
DIABETES CARE, 1996, 19 (01) :64-66
[5]   Metformin: An update [J].
Kirpichnikov, D ;
McFarlane, SI ;
Sowers, JR .
ANNALS OF INTERNAL MEDICINE, 2002, 137 (01) :25-33
[6]   Evidence for complement activation in ruptured coronary plaques in acute myocardial infarction [J].
Laine, P ;
Pentikäinen, MO ;
Würzner, R ;
Penttilä, A ;
Paavonen, T ;
Meri, S ;
Kovanen, PT .
AMERICAN JOURNAL OF CARDIOLOGY, 2002, 90 (04) :404-+
[7]   Metformin improves hemodynamic and rheological responses to L-arginine in MIDDM patients [J].
Marfella, R ;
Acampora, R ;
Verrazzo, G ;
Ziccardi, P ;
DeRosa, N ;
Giunta, R ;
Giugliano, D .
DIABETES CARE, 1996, 19 (09) :934-939
[8]   Metformin reduces serum C-reactive protein levels in women with polycystic ovary syndrome [J].
Morin-Papunen, L ;
Rautio, K ;
Ruokonen, A ;
Hedberg, P ;
Puukka, M ;
Tapanainen, JS .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2003, 88 (10) :4649-4654
[9]   ASSOCIATION OF SERUM C3 LEVELS WITH THE RISK OF MYOCARDIAL-INFARCTION [J].
MUSCARI, A ;
BOZZOLI, C ;
PUDDU, GM ;
SANGIORGI, Z ;
DORMI, A ;
ROVINETTI, C ;
DESCOVICH, GC ;
PUDDU, P .
AMERICAN JOURNAL OF MEDICINE, 1995, 98 (04) :357-364
[10]   Short term effect of atorvastatin and vitamin E on serum levels of C3, a sensitive marker of the risk of myocardial infarction in men [J].
Muscari, A ;
Bastagli, L ;
Poggiopollini, G ;
Tomassetti, V ;
Massarelli, G ;
Boni, P ;
Puddu, P .
CARDIOVASCULAR DRUGS AND THERAPY, 2001, 15 (05) :453-458